Richard T. Hauch

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia.

Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia.

Journal: Molecular and cellular pediatrics

Published: August 08, 2025

A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.

A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.

Journal: Leukemia & lymphoma

Published: March 20, 2025

Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.

Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.

Journal: Cancer immunology research

Published: August 06, 2024

Abdominal Aspergillosis - an Underdiagnosed Disease? Three Cases of Abdominal Aspergillosis in Severely Immunocompromised Infants.

Abdominal Aspergillosis - an Underdiagnosed Disease? Three Cases of Abdominal Aspergillosis in Severely Immunocompromised Infants.

Journal: Klinische Padiatrie

Published: January 30, 2024

Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT.

Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT.

Journal: Klinische Padiatrie

Published: April 12, 2023

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT.

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT.

Journal: Klinische Padiatrie

Published: February 27, 2023

Elevated RIPK3 correlates with disease burden in myelofibrosis.

Elevated RIPK3 correlates with disease burden in myelofibrosis.

Journal: Blood advances

Published: December 31, 2021

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.

Journal: Journal of cancer research and clinical oncology

Published: May 09, 2021

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Journal: European journal of haematology

Published: July 24, 2019

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Journal: Experimental hematology & oncology

Published: January 18, 2019

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Journal: Oncotarget

Published: November 14, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026